Feilding Mellen News Today

Open-label study will investigate the safety, efficacy and pharmacokinetics of BPL-003 in patients diagnosed with alcohol use disorder (AUD). BPL-003 is Beckley Psytech's patent-protected

Under an R&D partnership Beckley Psytech, dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, will jointly fund continuing development of Lophora ApS’ pipeline of proprietary NCEs for treatment-resistant depression, and other potential indications such as anxiety, post-traumatic stress disorder and substance abuse. Click to read more...

Press release content from Business Wire. The AP news staff was not involved in its creation.

Beckley Psytech bolsters pipeline of next-generation psychedelic medicines with research collaboration and strengthening of relationship with Lophora ApS Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckle...

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding

City investors are confident that psychedelics will be a vital tool in fighting depression and mental trauma

Beckley Psytech Limited, a UK private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that Cosmo Feilding

Beckley Psytech announces first cohort of psychotherapists have begun training for treatment resistant depression Phase 2 trials Training programme to be conducted in partnership with industry-leading educational company, FluenceInitiation of training represents key step to incorporate psychedelic-assisted psyc...

Beckley Psytech leads a new project focused on addressing  psychiatric and neurological conditions through the use of psychedelic medicines. - News - PharmaTimes